Olanzapine vs Quetiapine

How they're similar

Olanzapine and quetiapine are both second-generation atypical antipsychotics. Their overlap is broad and shapes how they're used in practice.

• Both are FDA-approved for schizophrenia and for acute mania in bipolar disorder. Both are used for bipolar maintenance and can be part of long-term treatment.
• Both block dopamine D2 receptors and serotonin 5HT2A receptors, which is the defining mechanism of the atypical class.
• Both carry the class boxed warning about increased mortality in elderly patients with dementia-related psychosis. Neither is a first choice for behavioral symptoms of dementia even though quetiapine is often used off-label in that setting.
• Both are strongly linked to weight gain, increased blood sugar, and increased cholesterol and triglycerides. The metabolic monitoring plan is the same for both: weight and blood pressure at baseline and follow-ups, fasting glucose and lipids at baseline, at three months, and then at least annually.
• Both can cause sedation, though quetiapine's sedation is more pronounced.
• Both are available as inexpensive generics and have been for years.
• Both can cause the antipsychotic side effects that come from any dopamine blocker, including movement effects, though at usual doses both are considered relatively low on that risk compared to older antipsychotics or to risperidone.

The overlap means that if a patient can tolerate one, they can often tolerate the other, and if a patient has significant metabolic problems on one, switching to the other is unlikely to solve that specific problem. This is a key point clinicians raise when a patient reports weight gain on olanzapine and asks about switching to quetiapine as a fix. It usually isn't.

How they differ

The differences show up in three main places: which conditions they're approved for, how they're used at different doses, and how sedating they feel. The table below summarizes the main points, with practical detail underneath.

Olanzapine tends to be the more potent antipsychotic on a head-to-head basis for acute mania and for psychotic symptoms. In inpatient settings for severe mania or florid psychosis, olanzapine is often chosen for that reason. Quetiapine works too, but at the doses needed for full antipsychotic effect, usually 400 to 800 mg a day, sedation is often significant and titration takes time.

Quetiapine has a separate FDA approval for bipolar depression, both for acute treatment and for maintenance. That approval matters because bipolar depression is one of the harder parts of bipolar disorder to treat, and the list of drugs approved for it is short. Olanzapine has an approval for bipolar depression only as Symbyax, which is a fixed combination of olanzapine and fluoxetine. Olanzapine alone isn't approved for bipolar depression. Quetiapine is also approved as an adjunct in major depressive disorder when a first antidepressant hasn't been enough, which expands its reach into treatment-resistant depression.

Sedation is where quetiapine stands out most. It's strongly sedating, especially in the first hours after a dose. This is partly because it hits histamine H1 receptors hard, similar to older antihistamines. That sedating quality has driven a large amount of off-label prescribing at low doses (25 to 50 mg) for insomnia, sometimes over years. Multiple professional societies and guideline documents caution against this practice, both because low doses still carry the metabolic risks and the mortality warning, and because there are safer options for chronic insomnia. Still, it's a widespread pattern that patients often ask about.

Quetiapine also causes orthostatic hypotension, meaning blood pressure that drops when a person stands up. This is especially prominent during titration, and it's one reason quetiapine has to be started at a low dose and stepped up gradually. Older patients are particularly at risk of falls from this effect. Olanzapine causes some orthostatic hypotension but usually less.

Formulations differ in a practical way. Olanzapine comes as regular tablets, dissolving tablets that dissolve on the tongue, an intramuscular form for acute agitation, and a long-acting injectable given every two to four weeks. Quetiapine comes as immediate-release tablets, which are usually taken twice a day, and extended-release tablets (Seroquel XR) taken once daily. Both dosing schedules are workable, and the XR form gives quetiapine a once-daily option.

Side effect tendencies

Weight gain and metabolic effects are the headline for both drugs. Head-to-head, olanzapine tends to be the worst offender for weight gain, but quetiapine is close, and both can produce substantial weight increases over months to years of treatment. Appetite often increases within the first weeks. Fasting glucose and lipid values commonly move in the wrong direction on either drug, sometimes without a large weight change. This is why the monitoring schedule matters. Catching a rising A1C early gives room to intervene, whether with dietary changes, exercise, adding metformin, or considering a switch.

Sedation runs higher on quetiapine, especially in the first hours after a dose. Many patients dose it at night for that reason. Daytime grogginess can persist, especially at higher doses. Olanzapine is also sedating but usually less so, and the sedation often eases somewhat over the first weeks.

Movement side effects are relatively uncommon on both at usual doses. Both are considered low-EPS agents, and both carry a lower risk than older antipsychotics like haloperidol. Tardive dyskinesia is still possible on either drug over years of use, and monitoring with the AIMS exam is part of routine care.

Prolactin elevation is generally mild with both drugs. This is a difference from risperidone or paliperidone, which raise prolactin significantly.

Orthostatic hypotension is more of an issue with quetiapine than olanzapine, particularly early in treatment. That means slow titration, checking blood pressure sitting and standing, and being especially cautious in older patients.

Both can cause dry mouth, constipation, and blurred vision from anticholinergic effects. Both can cause fatigue. Both can affect cognition in the sense of slowing thinking or blunting alertness, which some patients tolerate fine and others find hard to work through.

What tips the choice

Since the two drugs work about equally well for most cases of schizophrenia and bipolar mania, the choice usually comes down to the specific clinical target and to what the patient can tolerate.

A clinician might choose olanzapine when the primary target is acute mania or psychosis and antipsychotic potency matters more than avoiding sedation. It's a common choice in inpatient settings for rapid symptom control. It's also a reasonable choice when weight and metabolic burden are already high on another drug and the patient has done well on olanzapine before. Olanzapine's IM form makes it useful for acute agitation, and its long-acting injectable version fits patients who benefit from a monthly shot.

A clinician might choose quetiapine when the target is bipolar depression, which is one of quetiapine's specific FDA approvals as a single agent. It's also a natural choice for someone whose bipolar illness includes prominent depressive episodes rather than mania as the main problem. In treatment-resistant major depression, quetiapine is used as an adjunct to an antidepressant, again reflecting its specific approval there.

Sedation is often the practical dividing line. A patient with severe insomnia and agitation may benefit from quetiapine's stronger sedating effect. A patient who needs to work or function during the day and can't tolerate daytime grogginess may do better on olanzapine, or on a less sedating drug entirely.

Metabolic risk isn't a strong differentiator between these two. Both are heavy on the metabolic side. If a patient has significant metabolic problems, moving to aripiprazole, lurasidone, or another metabolically friendlier agent is usually a more meaningful change than switching between olanzapine and quetiapine.

Prior response weighs heavily. A patient who's done well on one of these drugs before usually goes back to that one. A patient who had a specific problem, like severe sedation on quetiapine or intolerable weight gain on olanzapine, would usually move away from that drug rather than try a similar one.

Common questions

Is it okay to use quetiapine just for sleep? This is common and controversial. Low-dose quetiapine (usually 25 to 50 mg at bedtime) is often prescribed off-label for insomnia because it's strongly sedating. The concern from most guideline documents is that even low doses carry the metabolic risks and the boxed warnings that come with antipsychotics, and there are other options for chronic insomnia that don't carry those risks. It can be a reasonable short-term option in some clinical situations, but as a long-term sleep aid it's usually not the first choice. If a person is using it that way, it's worth a conversation with a prescriber about whether there's a safer approach.

Which one causes more weight gain? Olanzapine tends to cause slightly more weight gain than quetiapine head to head, but both are among the worst offenders in the atypical class. Weight gain of 10 to 20 pounds or more in the first year isn't unusual on either drug. Switching from olanzapine to quetiapine to solve a weight problem rarely helps. If weight is a specific concern, options include working on diet and activity, considering metformin as an add-on, or switching to a metabolically friendlier drug like aripiprazole or lurasidone.

Can quetiapine treat depression by itself? Quetiapine is FDA-approved for bipolar depression as a single agent, and it's approved as an adjunct in major depressive disorder when a first antidepressant hasn't been enough. It isn't a standard first-line choice for uncomplicated major depression on its own, largely because of the side effect burden. For someone with bipolar disorder who's in a depressive episode, quetiapine is one of the drugs specifically studied and approved for that purpose.

Do I have to take quetiapine twice a day? Immediate-release quetiapine is usually taken twice a day, but extended-release quetiapine (Seroquel XR) is taken once a day. Many patients on higher doses use the XR form for that reason. Olanzapine is taken once daily.

Do I need labs while on either of these? Yes. Both drugs require metabolic monitoring. That means weight and blood pressure at every visit and fasting glucose and lipids at baseline, at three months, and then at least once a year. If any of those values move in the wrong direction, it's a conversation about diet, activity, add-on medications like metformin, or considering a switch. Regular monitoring is what makes long-term use of these drugs safer, not the drug itself.

Sources

This guide draws on current prescribing information and public health references. It is reviewed for clinical accuracy and updated as guidance changes.

1. U.S. Food and Drug Administration. Olanzapine (Zyprexa) prescribing information.
2. U.S. Food and Drug Administration. Quetiapine (Seroquel) prescribing information.
3. MedlinePlus, U.S. National Library of Medicine.
4. National Institute of Mental Health. Mental health medications.